comparemela.com

Latest Breaking News On - Zenas biopharma announces publication - Page 1 : comparemela.com

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD

New yorkUnited statesJake edmistonEdwarda foxKevin carmichaelGabriel friedmanJohn stoneZenas biopharmaPostmedia network incXencor incNational postProfessor of medicine at harvard medical schoolZenas biopharma announces publicationInvestigational treatmentRelated diseaseLancet rheumatology

vimarsana © 2020. All Rights Reserved.